Expert Second Opinion: Post-H. pylori Eradication Dyspepsia with Antral Gastritis

1. DIFFERENTIAL DIAGNOSIS & PRIMARY ASSESSMENT

Most Probable Diagnosis: Post-Infectious / Post-H. pylori Functional Dyspepsia (Epigastric Pain Syndrome subtype)

Ranked Differential Diagnoses

Critical Gap: Eradication Not Confirmed

2. PRESCRIPTION EVALUATION

2a. Syp Sucral O (Sucralfate + Oxetacaine) 1 tsp TDS

2b. Cap Rabfit DSR (Rabeprazole 20mg + Domperidone SR) 1 OD BBF

2c. Tab Tryptomer (Amitriptyline 10 mg) OD

• Has her prescriber documented that this is being used as a neuromodulator for a gut-brain disorder and not as an antidepressant? Patient counselling is critical — patients who are not informed sometimes stop the drug fearing "being labelled as psychiatric."
• Baseline assessment of depression/anxiety is warranted, as comorbid anxiety is found in ~40% of FD patients and would influence long-term neuromodulator selection.
• If no response at 10 mg by 4 weeks, titrate to 25 mg rather than discontinuing.

3. MANDATED NEXT STEPS IF SYMPTOMS DO NOT RESOLVE AFTER 15-DAY COURSE

Immediate Priority (Before Any Medication Change)

• Stop PPI (Rabeprazole) for ≥ 2 weeks before the test
• Test at ≥ 4 weeks post-antibiotic completion
• Use ¹³C-UBT (preferred) or stool antigen test (validated monoclonal ELISA)
• Do not use serology — it cannot confirm eradication

• Gallstones / biliary sludge (extremely common cause of dyspepsia in young women)
• Hepatomegaly, fatty liver
• Pancreatic pathology
• If not already done, this should precede the 15-day review

• CBC (rule out iron-deficiency anemia — H. pylori-associated occult blood loss/malabsorption)
• LFTs, serum amylase/lipase
• Anti-tTG IgA + total IgA (celiac serology — bloating is a core symptom)
• Thyroid function tests (hypothyroidism causes dysmotility)
• Blood sugar/HbA1c (diabetic gastroparesis, young-onset DM in India)
• H. pylori stool antigen if UBT not available

At 4–6 Weeks (If Symptoms Persist Despite Above)

• Unintentional weight loss > 5% body weight
• Progressive dysphagia
• Recurrent vomiting
• Palpable epigastric mass
• New iron-deficiency anemia
• Family history of gastric cancer

4. EVIDENCE-BASED DIET & LIFESTYLE ROADMAP

Dietary Modifications (Implement Immediately)

Lifestyle Modifications (Implement Immediately)

• Stress reduction is therapeutic, not adjunctive. In a 37-year-old female, psychosocial stressors are a documented modulator of gut-brain axis activity. Mindfulness-based stress reduction (MBSR) has RCT data for functional GI disorders. Refer to clinical psychologist if behavioral component is prominent.
• Physical activity: Brisk walking 30 minutes/day, 5 days/week — moderate exercise is associated with lower FD prevalence and improves gastric emptying.
• Smoking: If applicable, cessation — nicotine delays gastric emptying and impairs mucosal healing.
• Sleep hygiene: Amitriptyline 10 mg OD at night will aid sleep quality as a secondary benefit; maintain a consistent sleep schedule. Poor sleep is both a trigger and a consequence of functional GI disorders.
• Posture after meals: Encourage a 15–20 minute light walk post-meals rather than lying down immediately.

CLINICAL SUMMARY & MANAGEMENT CHECKLIST

IMMEDIATE (This Week):
☐ Order UBT (13C) or stool H. pylori antigen — OFF PPI for ≥2 weeks before test
☐ USG Abdomen (hepatobiliary) — if not already done
☐ CBC, LFTs, TFTs, Anti-tTG IgA, RBS/HbA1c
☐ Patient counselling: explain neuromodulator use (not "psychiatric" drug)
☐ Initiate dietary modifications (see table above)

AT 15-DAY REVIEW:
☐ Review UBT result
  → UBT POSITIVE: Switch to salvage therapy (Bismuth Quadruple × 14 days)
  → UBT NEGATIVE: Confirmed eradication → continue current FD management
☐ Titrate Tryptomer 10 mg → 25 mg if partial response or poor tolerance
☐ Continue Rabfit DSR for total 4–6 weeks
☐ Sucral O: can stop at 15 days or continue up to 4 weeks max

AT 4–6 WEEKS:
☐ If no improvement: gastric emptying study
☐ Rome IV criteria reassessment
☐ PHQ-9 / GAD-7 screening
☐ Consider referral: GI psychology / cognitive behavioural therapy
☐ Consider adding buspirone 10 mg TDS AC (5-HT1A agonist — evidence for fundic accommodation in FD) if bloating predominant

Disclaimer: This analysis is intended as a clinical decision-support second opinion for a qualified physician. All final treatment decisions remain the responsibility of the treating clinician with direct patient access.